EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Video and podcast roundups

Which YouTube videos are worth assigning to clinical and compliance teams?

Dose Diligence research deskSection 07 · Page 3 of 9Last updated 17 Nov 2026

1. What should clinicians understand about compounded obesity medicines?

Title: ENP107: Compounded Obesity Medications
Watch: Endocrine Society on YouTube
Listen and verify: Official episode page

Who and when: Host Aaron Lohr interviews Michael Weintraub, MD, an endocrinologist at NYU Langone. Published December 3, 2025. Evidence: publisher-notes-backed. The Endocrine Society discloses support from Lilly. Episode details.

Key takeaways: The episode frames the clinical questions around compounded obesity medicines: why shortage-era demand developed, what the absence of FDA approval means, and what doctors and patients should consider about safety and efficacy. Its value is establishing a shared clinical vocabulary before commercial discussions—not identifying a preferred supplier. Publisher summary. (endocrine.org)

Our procurement application: Ask the medical director to produce a short terminology guide distinguishing an approved medicine, a compounded preparation and a suspected counterfeit. Then review whether the clinic’s intake scripts and supplier presentations preserve those distinctions.

Limitation: Manufacturer support should remain visible when circulating the episode. It is neither independent pharmacy testing nor a product-specific legal assessment.

2. Which questions should a compounding pharmacy be prepared to answer?

Title: Navigating GLP-1 Compounding: FDA and State Boards of Pharmacy Perspectives (On-Demand Webinar)
Watch: Frier Levitt on YouTube

Who and when: Lucas Morgan and Martha Rumore. The session aired January 29, 2025; YouTube publication was January 30, 2025. Evidence: video description and organiser notes. Video description; series page.

Key takeaways: The published syllabus connects 503A requirements with shortage-list changes, sterile-compounding standards, state-board inspections and non-resident pharmacy issues. It also discusses manufacturer petitions concerning products that may be difficult to compound. These are useful categories for organising a diligence request. Published syllabus.

Our procurement application: Create separate evidence requests for the actual preparation, facility, sterile operations and destination states. Do not let a single “compliant pharmacy” presentation answer all four questions.

Limitation: This is historical framework material, not November 2026 clearance. Read the regulatory updates below before applying any shortage-era discussion. It is law-firm education, not advice on the buyer’s particular contract.

Sources cited on this page

  1. youtube.com · Source 1 ↗https://www.youtube.com/watch?v=9YZFfBj_Ybk
  2. endocrine.org · Source 2 ↗https://www.endocrine.org/podcast/enp107
  3. endocrine.org · Source 3 ↗https://www.endocrine.org/podcast/enp107?utm_source=openai
  4. youtube.com · Source 4 ↗https://www.youtube.com/watch?v=a0edKHk28lU
  5. frierlevitt.com · Source 5 ↗https://www.frierlevitt.com/webinars/navigating-glp-1-compounding-2-part-webinar-series/
Section sources →